【摘要】：目的觀察恩替卡韋對慢性乙型病毒性肝炎(CHB)患者血清乙肝病毒DNA(HBV-DNA)、乙肝表面抗原(HBs Ag)、乙肝e抗原(HBe Ag)定量的影響。方法選取CHB患者160例,均給予恩替卡韋0.5 mg/d空腹口服,持續(xù)治療96周。觀察所有患者治療前、治療12、24、48及96周后HBV DNA、HBs Ag、HBe Ag定量以及谷氨酸氨基轉(zhuǎn)移酶(ALT)水平,計算HBV DNA、HBe Ag轉(zhuǎn)陰率及ALT復(fù)常率,分析HBV DNA變化與HBs Ag、HBe Ag、ALT的相關(guān)性。結(jié)果隨治療時間延長,患者HBV DNA、HBe Ag定量及ALT水平逐漸降低(F=11.562、28.034、22.417,P0.01);HBe Ag轉(zhuǎn)陰率、HBV DNA轉(zhuǎn)陰率以及ALT復(fù)常率逐漸增加;治療前、治療12及24周時,HBV DNA與HBs Ag滴度負(fù)相關(guān)(r=-0.383、-0.293、-0.224,P0.05或P0.01)、與HBe Ag滴度正相關(guān)(r=0.441、0.392、0.326,P0.05或P0.01)。結(jié)論恩替卡韋治療CHB療效確切,可有效促進HBV DNA、HBe Ag轉(zhuǎn)陰率及ALT復(fù)常。治療早期,HBV DNA與HBs Ag負(fù)相關(guān)、與HBe Ag呈正相關(guān),治療后期無顯著相關(guān)性,治療過程中,應(yīng)聯(lián)合多項指標(biāo)綜合評價療效。
[Abstract]:Objective to observe the effect of entecavir on serum hepatitis B virus DNA (HBV-DNA) and hepatitis B surface antigen (HBs Ag), hepatitis B e antigen (HBe Ag) in patients with chronic viral hepatitis B (CHB). Methods 160 patients with CHB were treated with entecavir 0.5 mg/d for 96 weeks. Before treatment, 24 weeks, 48 weeks and 96 weeks after treatment, the quantity of HBV DNA,HBs Ag,HBe Ag and the level of glutamate aminotransferase (ALT) were observed, the negative conversion rate of HBV DNA,HBe Ag and the recovery rate of ALT were calculated, and the changes of HBV DNA and HBs Ag,HBe Ag, were analyzed. The correlation of ALT. Results with the prolongation of treatment time, the quantity of HBV DNA,HBe Ag and the level of ALT decreased gradually (F 鈮，

本文編號：2489900